CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
58 hedge funds and large institutions have $29.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 9 closing their positions.
12% more capital invested
Capital invested by funds: $26.7M → $29.7M (+$3.08M)
5% less funds holding
Funds holding: 61 → 58 (-3)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.09M |
| 2 |
TA
Tiedemann Advisors
New York
|
+$139K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94.9K |
| 4 |
CG
Caprock Group
Boise,
Idaho
|
+$62.2K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$62.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.6M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$248K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$209K |
| 4 |
Goldman Sachs
New York
|
-$98.5K |
| 5 |
Millennium Management
New York
|
-$97.8K |
CTIC Hedge Fund Activity: Q4 2016 in Review
58 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2016, worth a combined $29.7M — up 12% from $26.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CTIC and 8 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $1.09M. The largest seller was Fidelity Investments, cutting an estimated $1.6M.
- 58 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2016, down from 61 in Q3 2016.
- Funds reported $29.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2016, up 12% quarter-over-quarter.
- 8 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2016 and 9 closed out, a net change of -1 holder.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2016 was Stonepine Capital Management, an estimated $1.09M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2016 was Fidelity Investments, an estimated $1.6M sold.
Based on aggregated 13F filings for Q4 2016.